Serum interleukin‐6 levels in response to methotrexate treatment in psoriatic patients

Elango, Tamilselvi; Dayalan, Haripriya; Subramanian, Swapna; Gnanaraj, Pushpa; Malligarjunan, Hemamalini

doi:10.1016/j.cca.2012.05.007

Cited by 35 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following treatment with methotrexate, adipose tissue from obese mice produced less proinflammatory (TNF‐α, IL‐6, leptin) and more anti‐inflammatory mediators (adiponectin and IL‐10) associated with reduced macrophage infiltration and inflammation (DeOliveira et al, ). In addition, methotrexate down‐regulates the expression of adhesion molecules (ICAM‐1, E‐selectin, VCAM‐1) in human biopsies rich in inflammatory infiltrate (Dahlman‐Ghozlan et al, ) and circulating levels of IL‐6 in psoriatic patients (Elango et al, ). All these activities support a potential effect of methotrexate in the treatment of atherosclerosis.…”

Section: Ongoing Rctsmentioning

confidence: 99%

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Welsh

Grassia

Botha

et al. 2017

British J Pharmacology

138

109

View full text Add to dashboard Cite

Data from basic science experiments is overwhelmingly supportive of the causal role of immune‐inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune‐inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.Linked ArticlesThis article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc

show abstract

Section: Ongoing Rctsmentioning

confidence: 99%

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Welsh

Grassia

Botha

et al. 2017

British J Pharmacology

138

109

View full text Add to dashboard Cite

show abstract

“…Considering the cost, it would be expedient to predict the chance of successful treatment before the start of ustekinumab therapy. Studies have focused on alterations in serum proteins during treatment, and have correlated these with the clinical response to systemic treatment including methotrexate and ustekinumab . However, only a limited number of cytokines were studied and no predictors of therapeutic response were found.…”

Section: Up‐ (Red) and Downregulated (Green) Heatmap Cytokines Basedmentioning

confidence: 99%

“…Studies have focused on alterations in serum proteins during treatment, and have correlated these with the clinical response to systemic treatment including methotrexate and ustekinumab. [2][3][4][5][6] However, only a limited number of cytokines were studied and no predictors of therapeutic response were found.…”

mentioning

confidence: 99%

Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study

et al. 2015

View full text Add to dashboard Cite

“…In a clinical study with psoriatic patients, treatment with methotrexate downregulated serum IL-6 levels. Since this cytokine is known to be over-expressed in psoriasis, a reversal of this may result in a therapeutic effect, suggesting this type of effect to be positive for psoriasis [21]. …”

Section: Discussionmentioning

confidence: 99%

Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis

Gujjar

Arbiser

Coulon³

et al. 2015

Journal of Drug Targeting

View full text Add to dashboard Cite

Purpose Pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (PTTC) is a cinnamate tetraester with proteasome inhibitor activity, which may be used as a topical treatment in psoriasis, but has a computed log P of 23. The objective of this in vitro study was to determine the intradermal delivery, skin irritation and potential efficacy of PTTC in treating psoriasis. Methods Solubility studies were performed to find a suitable vehicle for PTTC. Permeation studies were performed with microneedle-treated skin. A cell culture irritation test was dosed with a positive control, negative control and PTTC. An MTT assay was performed to evaluate cell viability and irritancy. Psoriatic cell culture was also dosed with PTTC and IL-6 levels were determined by ELISA. Results Solubility was greatest in dimethyl sulfoxide and ethyl pyruvate, with dimethyl sulfoxide delivering a greater amount (2343.41 ± 384.26 μg) into stratum corneum. PTTC alone as well as topical PTTC emulsion formulation were found to be non-irritant with cell viability of 69.0 ± 5.64% and 74.6 ± 5.03%, respectively. Treatment with neat PTTC slightly reduced IL-6 levels and PTTC emulsion significantly reduced IL-6 levels to 92.53 ± 12.74 pg/ml compared to basal levels (141.69 ± 8.41 pg/ml). Conclusion PTTC can be delivered intradermally to potentially treat psoriasis.

show abstract

Serum interleukin‐6 levels in response to methotrexate treatment in psoriatic patients

Cited by 35 publications

References 35 publications

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study

Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis

Contact Info

Product

Resources

About